Wang, C., Xu, Y., Lin, Y., Mao, F., Guan, J., Shen, S., Zhang, Y., Zhang, X., Wang, X., Zhong, Y., Pan, B., Li, Y., Huang, X., Peng, L., Cao, X., Yao, R., Lang, J., Zhou, Y., Sun, Q. (2026). Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.533